Inyx, Inc. (IYXI) Research

Inyx, Inc. is a specialized pharmaceutical firm that conducts its operations via wholly-owned subsidiaries throughout the United States, Canada, and Europe. Its core business involves creating and producing both prescription and over-the-counter medications. The company's production capabilities extend to hydrocarbon aerosols for dermatological and topical drug delivery, as well as various inhaler types—metered-dose and dry-powder—specifically designed for respiratory issues. Additionally, it produces metered-dose nasal and throat pumps and sprays, alongside sterile saline solutions and injectable products. Significant research and development efforts are channeled into advancing inhalation-therapy drug delivery devices and methods. This focus also encompasses the development of generic prescription and over-the-counter aerosol pharmaceuticals targeting a broad spectrum of applications, including respiratory, allergic, dermatological, topical, and cardiovascular conditions. Under development are several proprietary product candidates, such as generic non-chlorofluorocarbon (CFC) or hydrofluoroalkane (HFA) respiratory inhalants (for both single and combination drugs), non-CFC propelled oral sprays intended for cardiovascular disorders, wound irrigation and cleansing sprays leveraging innovative barrier technologies, and anti-inflammatory nasal pumps. Moreover, Inyx extends its expertise by offering specialized pharmaceutical development and manufacturing consulting services to the global healthcare sector. Founded in 2000, the company maintains its principal offices in New York, New York.

Open Inyx, Inc. (IYXI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.